Skip to main content
. 2022 Feb 16;5(2):e2146912. doi: 10.1001/jamanetworkopen.2021.46912

Table 1. Baseline Characteristics Among Treatment Groups Before Propensity Score Matching.

Characteristics No. (%) P value
Neoadjuvant Surgery alone Adjuvant
No. (%) 101 (1.6) 3145 (49.2) 3145 (49.2)
Age, median (IQR), y 59 (52-66) 72 (63-81) 65 (57-72) <.001
Sex
Male 32 (1.7) 900 (49.1) 900 (49.1) .80
Female 69 (1.5) 2245 (49.2) 2245 (49.2)
Race and ethnicitya
Hispanic >12 (>1.6) 406 (53.3) 343 (45.0) .06
Non-Hispanic
Black <11 (<1.3) 392 (46.4) 442 (52.4)
White 66 (1.6) 2024 (49.4) 2004 (48.9)
Insurance status <.001
Uninsured <11 (<4.8) 112 (48.9) 116 (50.7)
Private 65 (3.1) 790 (38.1) 1220 (58.8)
Medicaid 11 (2.0) 247 (45.6) 284 (52.4)
Medicare >13 (>0.1) 1925 (56.9) 1438 (42.5)
Income, $
<40 227 18 (1.4) 675 (53.2) 576 (45.4) .02
40 227-50 353 15 (1.1) 696 (49.7) 688 (49.2)
50 354-63 332 26 (1.7) 727 (47.6) 774 (50.7)
≥63 333 40 (1.9) 1001 (47.6) 1060 (50.5)
Charlson Comorbidity Index score
0 77 (1.8) 2033 (46.3) 2284 (52.0) <.001
1 >13 (>1.0) 786 (53.4) 664 (45.1)
≥2 <11 (<2.1) 326 (62.0) 197 (37.5)
Facility type
Academic 61 (2.4) 1181 (46.3) 1310 (51.3) <.001
Nonacademic 38 (1.0) 1924 (51.6) 1767 (47.4)
Nodal status
Negative 28 (1.7) 925 (55.2) 722 (43.1) <.001
Positive 53 (2.2) 912 (37.3) 1482 (60.6)
No nodes examined 18 (0.8) 1294 (57.8) 928 (41.4)
Margin
R0 75 (1.9) 2088 (52.2) 1836 (45.9) .13
R1 <11 (<1.1) 418 (43.5) 532 (55.4)
R2 <11 (<7.4) 61 (40.9) 87 (58.4)
Stage
II 31 (1.0) 1850 (61.8) 1111 (37.1) <.001
III 51 (2.2) 939 (41.0) 1298 (56.7)
IV 19 (1.7) 356 (32.0) 736 (66.2)
Overall survival, median (95% CI) 27.0 (20.5-33.6) 17.6 (12.4-22.8) 22.3 ()19.4-25.3 .13
a

Race and ethnicity data were self-reported; for this study, terms were classified for reporting convenience.